Kurt Mussina, CEO, Paradigm Clinical Research, describes his organization’s nine locations not as separately managed sites, ...

Sequoia’s Dan White and Dr. Tom Kreamer touch on why sponsors and CROs should treat a site network as one centralized ...

Kurt Mussina, CEO, Paradigm Clinical Research, acknowledges that scale matters but pushes back on the idea that it should ...

Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building ...

Jennifer Byrne, CEO and founder, Javara, credits SCRS as a valuable part of the broader site landscape, pointing to its role ...

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the shift from narrow AI tools to a continuous learning ...

Trially CEO Kyle McAllister explains why transparent AI reasoning is essential for trial patient matching. Kyle McAllister, ...

Kyle McAllister, co-founder and CEO, Trially, explains that under tight research preassure, the smaller, less visible tasks ...

In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into ...

ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than ...

ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another ...

A new ACT FAQ article examines who decides what clinical trials measure. Endpoints are shaped mainly by expert clinical teams ...